Immunome Announces Submission for Publication of Pre-clinical Research for SARS-CoV-2 Treatment and Prophylaxis


EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The manuscript is concurrently undergoing scientific peer review for potential publication.

IMM-BCP-01 contains three monoclonal, antibodies that bind to non-overlapping regions of the spike protein, including highly conserved epitopes. In preclinical testing, the antibodies exhibit combinatorial effects against multiple SARS-CoV-2 strains, including CDC variants of concern, and significantly reduces viral load in the lungs of hamsters infected with a SARS-CoV-2 reference strain.

Immunome’s preclinical research demonstrates:

  • The three antibodies, derived from human immune response, bind to the spike protein in a non-competitive manner.
    • The first antibody binds to a sub-dominant epitope of the spike protein, which appears to be broadly conserved across all current and former SARS-CoV-2 variants of concern as well as other Betacoronaviruses and SARS-COV-1.
    • The second antibody is also directed at a broadly conserved epitope and exhibits an avidity-based binding mechanism.
    • The third antibody binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop.
  • As a cocktail, the three antibodies demonstrate enhanced anti-viral activity.
    • Efficacious in pseudovirus neutralization against the CDC variant of concern, Delta.
    • Shows equal or better activity against live virus in the reference and the variants tested to-date (Alpha, Beta and Gamma).
    • Potent activation of phagocytosis and complement fixation – known to be critical for in vivo treatment efficacy
  • In both treatment and prophylactic settings, at corresponding doses of up to 9 mg/kg, the cocktail potently reduced live viral titers by approximately 3.2 – 4 logs (or up to 10,000-fold) in the lungs of Syrian hamsters infected with SARS-CoV-2 virus
  • Published data2 for Sotrovimab (GSK and VIR Biotechnology), at 30 mg/kg, the highest dose tested in the prophylactic setting, show approximately a 2 log (or 100-fold) reduction in live viral titer in the lungs of Syrian hamsters infected with SARS-COV-2
READ:  QVC+ and HSN+ Streaming Experience Launches on Samsung Smart TVs

“SARS-CoV-2 and its emerging variants continue to be a major ongoing public health concern,” said Susan R. Weiss, Ph.D., Professor and Vice Chair of the Department of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, Co-Director at the Penn Center for Research on Coronaviruses and Other Emerging Pathogens, and a member of Immunome’s COVID-19 Advisory Board.1 “Evidence in the literature demonstrates that a combination of antibodies offers better protection than a single antibody and in addition a higher barrier to mutational drift. This factor must be carefully considered in the overall development of antibody therapeutics against this virus.”

“The potency and breadth of activity shown across multiple variants highlights the ability of our antibody cocktail to provide broad protection and potent viral load reduction in the widely used Syrian Hamster model. We believe that the three carefully selected antibodies, from the hundreds that we isolated, each provide unique antiviral properties and that, when combined as a cocktail in our research, these antibodies appear to mimic the natural human immune response,” said Purnanand Sarma, PhD, President & CEO of Immunome. “The preclinical efficacy of IMM-BCP-01 that we observed in Syrian hamsters infected with SARS-CoV-2 is promising and, if translated to humans, supports potential non-intravenous delivery.”

This study was funded by the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), in collaboration with the Defense Health Agency (DHA).

  1. Weiss receives compensation as member of Immunome’s COVID-19 Advisory Board.
  2. Cathcart, A.L et al bioRxiv 2021.03.09.434607
READ:  Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.